A small study involving Keytruda (pembrolizumab) showed that the cancer drug has been effective in shrinking or removing cancer tumors. With this, the U.S. Food and Drug Administration immediately approved the drug for patients with locally advanced or metastatic urothelial carcinoma.
The Keytruda is the first drug that has been approved for treating tumors that share a certain genetic profile, and thousands of patients are expected to benefit from it every year, according to The New York Times. Even without a control group, or a set of patients that did not receive the drug to compare with, the results are compelling and convincing.
The study, originally released in the Science journal, saw eighty-six patients participating in the trial. Sixty-six of them had tumors that shrank significantly. Among the 66 patients, 18 patients had their tumors disappeared.
Dr. Jack Jacoub, a medical oncologist at MemorialCare Cancer Institute, said that the results of the study, which was published in the journal Science last week, showed the effectiveness of targeting the immune system to treat cancer. This is in contrast to the common classification of cancers based on their location in the body. With pembrolizumab, the cancer cells are unmasked so that the immune system can identify and destroy them.
Keytruda is made by Merck & Co. and costs around $156,000 a year for patients with advanced lung, melanoma and bladder tumors. The study is ongoing, and the drug maker has also begun a trial to pair Keytruda with CTLA4 candidate MK-1308, per FiercePharma.
Merck hosted an encouraging analyst meeting at ASCO last week, and Morgan Stanley remains bullish on growth prospects of its new cancer drug. The Keytruda is the main catalyst for the company’s stock this year, which Zacks Investment Research rated “buy” in a research note published on May 26, according to a report from Smart Stock News.
When new travel fees fly under the radar
In the travel industry, new fees and restrictions tend to have one thing in common: they are introduced without fanfare...
What would happen if Venezuela and the Middle East couldn’t access oil?
The United States continues to pump out record amounts of oil.
Trump’s chances in the 2020 election
How will the US economy fare in the upcoming 2020 presidential elections?
What to expect from the IRS’ revised cryptocurrency guidance?
Another year, another batch of investors left in the dark.
The silver lining in pursuing foreclosed homes
Foreclosure is one real estate issue turning the buying and selling process messy.
- Business4 weeks ago
Why big data and machine learning is the future for commercial real estate
- Sponsored4 weeks ago
What the second half of 2019 holds for Bitcoin in Africa
- Crypto4 weeks ago
Using blockchain in high fashion
- Sponsored3 weeks ago
4 misconceptions retailers still have about sales analytics